Celator Pharma Cash Flow - Quarterly (NASDAQ:CPXX)

Add to My Stocks
$30.24 $0 (0%) CPXX stock closing price Jul 14, 2016 (Closing)

The cash flow statement is one of the reports a publicly traded company like Celator Pharma needs to disclose. In simple terms, the cash flow statement measures the cash that has come into the company, and the cash that has gone out during a given period, while the other statements, the income statement and balance sheet, give details about Celator Pharma profits and Celator Pharma debt. Celator Pharma had cash and cash equivalents of $- at beginning of the quarter and $67.54M at quarter end of 2016 Q1. Celator Pharma cash flow analysis tells whether or not the company has enough cash for its day to day activities, and for investing for future growth. Celator Pharma has a positive cash and cash equivalents change of $44.28M.

View and download details of Celator Pharma cash flows for latest & last 40 quarters
show more
Fiscal year is Jan - Dec2016 Q12015 Q4
Net Income Cash Flow
Depreciation Depletion Amortization Cash-Flow--
Net Increase (Decrease) in Assets Liabilities-0.3M1.39M
Cash From (used in) Discontinued Operations--
Other Adjustments Net-2.23M
Net Cash from (used by) Operating Activities
Increase (Decrease) in Prop Plant And Equipment--0.05M
Acquisition Disposition of Subsidiaires--
Increase (Decrease) in Investments--
Other Cash Inflow (Outflow) from Investment Activities--
Net Cash from (used by) Investment Activities
Issuance (Purchase) of Equity Shares51.1M2.07M
Issuance (Repayment) of Debt Securities-1.29M4.57M
Increase (Decrease) in Bank & Other Borrowings--
Payment of Dividends & Other Cash Distributions--
Other Cash from (used by) Financing Activities-0.41M-0.23M
Net Cash from (used by) Financing Activities
Effect of Exchange Rate Changes on Cash--0.03M
Net Change in Cash & Cash Equivalents
Cash & Equivalents at Beginning of Year--
Cash & Equivalents at Year End67.54M23.25M
All figures in USD. M: Millions of USD, B: Billions of USD.

Celator Pharma stock comparison chart provides an easy way to compare the stock price with peers along with details of Celator Pharma stock price history.
The statement of cash flows can be categorized into the following main sections:

  • Celator Pharma has cash of $67.54M on hand. A healthy amount of cash on hand is necessary for any company. Cash has an opportunity cost associated with it, and too much cash in bank may mean that the firm has no or limited growth plans. Hence its important to track the Net Change in Cash and Cash Equivalents along with the Celator Pharma stock price.
  • Cash Flow from operating activities: This is the cash that the company receives from ongoing operations. Celator Pharma lost $-5.1M cash from operations. It is important to check this to see where the company is getting its money from.
  • Cash Flow from investment activities: Celator Pharma used $- cash due to investment activities. It includes the use of cash outside of normal day to day activities like buying fixed assets, plant and machinery etc.
  • Cash Flow from financing activities: The cash inflow/outflow from financing activities was $49.39M for Celator Pharma. The money accounted for under this head comes from external sources which includes lenders, investors and shareholders. Positive cash flow is generated when the company gets cash because of issuance of stocks or bonds. Similarly negative cash flow is generated when shares are repurchased, dividend payments are made, and loans or interest on loans are paid back.

Quarterly Cash Flow Statements For Celator Pharmaceuticals Inc Peers

CTI BioPharma cash flow, Mallinckrodt cash flow, Relypsa cash flow